|
|
|
1-10 employees
View all
|
|
Pharmaceuticals
|
|
166 Fifth Ave, 2nd Flr, New York, NY 10010, US
|
|
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.
|
ENB Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used ENB Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact ENB Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.